Woman and Man
- | Country :
- Australia
- New Zealand
- | organs : -
- | Specialty : -
Extract
The study aims to assess the safety and tolerability of subcutaneous Ig NextGen 16% in patients with Primary Immune Deficiency who require Immunoglobulin (Ig) G replacement therapy. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation.
Inclusion criteria
- Primary Immune Deficiency